Max Hodak, co-founder of Neuralink, will take the stage at TechCrunch Disrupt 2026 to argue that the screen era is coming to an end. His talk centers on brain-computer interface technology and screen-free interaction models that bypass traditional displays entirely.
Hodak's appearance signals a broader industry pivot away from graphical user interfaces that have dominated computing for four decades. Neuralink, Elon Musk's neurotechnology company, has positioned itself as the leading commercializer of high-bandwidth brain-computer interfaces. The company received FDA approval for human trials in May 2023 and implanted its first wireless brain chip in a patient in January 2024.
The timing of Hodak's Disrupt keynote reflects accelerating momentum in neural interface development. Neuralink competes in a crowded field that includes established players like BrainGate (Stanford), Synchron, and Paradromics, each working on different approaches to brain-computer communication. Hodak's specific focus on screen-free interfaces positions Neuralink's technology as not just a medical tool but a fundamental shift in human-computer interaction itself.
His vision likely encompasses both consumer and clinical applications. In the medical context, brain-computer interfaces can restore motor function to paralyzed patients or provide direct neural communication for locked-in syndrome. The consumer angle remains speculative but intriguing: imagine replacing smartphones and laptops with direct neural input-output that requires no visual display. This represents a more radical departure than augmented reality glasses or mixed-reality headsets, which still rely on screens or visual overlays.
Neuralink's first human implant patient demonstrated this potential in May 2024, when the company announced the recipient could control a computer cursor and play video games using only thought. That breakthrough proved the core technology works in human brains, not just animal models. The company plans multiple implants this year as it advances from proof-of-concept toward therapeutic applications.
Hodak left Neuralink in June 2021 to start Science, a venture focused on neural interfaces for medical applications, before returning to deeper involvement in the neural interface space. His perspective bridges both the startup mentality and the deeper research requirements of neurotechnology. At Disrupt, his audience will include investors evaluating whether brain-computer interfaces represent the next major computing platform shift, entrepreneurs considering entry into the space, and tech leaders assessing how quickly neural interfaces will displace traditional input methods.
The presentation arrives as debates intensify around emerging tech regulation. Brain-computer interfaces raise privacy and security questions that exceed those posed by conventional interfaces. Hodak's presence at Disrupt underscores that neurotechnology has moved from fringe research into mainstream startup and venture capital discourse.
Attendees can register before September 25 to receive discounts on event passes. Hodak's talk will likely attract standing-room-only crowds, given the intersection of neuroscience, consumer tech, and philosophical questions about human-computer fusion that his topic encompasses.